AxoGen, Inc.

AXGN Healthcare Medical Devices

AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.1%, EPS fell 400.0%, free cash flow fell 17.4% and total debt fell 72.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

34.62 1.01 −2.83%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−110×
Dividend yield
—
F-score
5/9
Altman Z
9.23
Beneish M
−2.73
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(18.21%) (17.96%) (13.49%) (1.90%)

+8 more TTM periods

Piotroski F-Score
5 5 5 6
ROA
(13.15%) (12.95%) (7.38%) (1.03%)
ROIC
(4.99%) (3.48%) (3.25%) 1.68%
Return on Tangible Assets
(13.29%) (13.01%) (8.79%) (1.24%)
Average Days of Receivables
49.59 43.40 42.41 52.32
Free Cash Flow per Share
0.12 0.15 (0.10) 0.04
Free Cash Flow
6.51 7.66 (4.78) 2.06
Other line items

Show all line items

Columns are period end dates